David Mannino is co-founder and chief medical officer of the COPD Foundation. He's an internal medicine doctor with a specialty in pulmonary, critical care, and sleep medicine at University of ...

AstraZeneca (AZN) stock is in focus as tozorakimab marks a new Phase 3 trial win in chronic obstructive pulmonary disease, a ...

Key opinion leaders highlight the triple therapy approach from the most recent GOLD guidelines, including ICS, long-acting beta-agonist (LABA), and long-acting muscarinic antagonist (LAMA). Jeffrey D.

Among patients with blood eosinophil counts greater than or equal to 150 cells/µL, the reduction in the annual rate of moderate to severe COPD exacerbations was found to be nominally significant. The ...

April 20 (Reuters) - AstraZeneca said on Monday its experimental treatment tozorakimab showed a "meaningful reduction" in ...

The maintenance inhalers available for obstructive lung disease are long-acting beta-agonists (LABAs), long-acting muscarinic antagonists (LAMAs), and inhaled corticosteroids (ICSs). We use all three ...

Effective treatment often requires you to take medications to better manage symptoms or stop taking medications if a doctor advises that you no longer need them. Finding the right dosages and ...

COPD, or chronic obstructive pulmonary disease, is a group of life-changing lung diseases that include emphysema and chronic bronchitis. 1 Those living with COPD can experience coughing, wheezing, ...

Are you finding that your chronic obstructive pulmonary disease (COPD) is making it harder to do the things you enjoy? Canceling plans more often? Missing work due to flare-ups? It could mean your ...